ntraaortic balloon pumping (IABP) is widely used in patients with cardiogenic shock, as well as in many other situations such as support for high risk angioplasty, refractory congestive heart failure, and post-myocardial infarction unstable angina. 1 The effects of IABP are considered to be a reduction in myocardial oxygen demand because of systolic left ventricular (LV) unloading and an increase in coronary blood flow. Although the former effect is well recognized, the latter effect remains controversial, 2-6 because previous studies have reported that coronary blood flow during IABP either increased 2,6 or remained unchanged. 3, 7 Percutaneous coronary intervention (PCI) is used as a treatment for acute myocardial infarction (AMI), and one of its major complications is the angiographic no-reflow phenomenon. Once this phenomenon occurs, the prognosis is extremely poor. [8] [9] [10] [11] Although IABP is sometimes used in such patients to increase the diastolic coronary blood flow, there is little available information regarding the effects of IABP on the angiographic no-reflow phenomenon. The purpose of the current study was to examine whether IABP augments diastolic coronary flow in patients with the noreflow phenomenon after PCI for anterior AMI. We used transthoracic Doppler echocardiography (TTDE), which enables evaluation of the flow in the distal left anterior descending artery (LAD) 12,13 to assess the coronary flow velocity during IABP counterpulsation, and we compared the effects of IABP between angiographic no-reflow and good reflow patients.
or after insertion of the IABP. PCI to the proximal LAD was performed within 12 h after the onset of chest pain. The intraaortic balloon inflation was initiated at the aortic dicrotic notch, and deflation was set on the R wave with manual inflation and deflation adjustments. Coronary stenosis was evaluated by multiple projections using the Philips quantitative coronary analysis system. A stenosis was considered significant if there was >75% lumen diameter narrowing in at least 1 projection. The thrombolysis in myocardial infarction (TIMI) score 14 was obtained from the final coronary angiography. In this study, angiographic no-reflow was defined as TIMI 1 and TIMI 2 with severe flow delay, and good reflow was defined as TIMI 3 flow. TIMI 2 flow patients with mild flow delay were excluded, in order to enhance the differentiation between good reflow and no-reflow patients. Microvascular perfusion was evaluated by both myocardial blush score 15 and epicardial coronary flow velocity pattern. 16, 17 
Coronary Flow Velocity Measurements by TTDE
Echocardiographic examinations during IABP were performed with a SEQUOIA C256 (Siemens Medical) using an Acuson 7V3c transducer in the coronary care unit immediately after coronary angiography or angioplasty. The assist ratio of IABP was set at 2:1 to allow comparison of the coronary flow velocity during augmented beats with that during non-augmented beats. All data were obtained during 2:1 balloon pumping. The aortic pressure, heart rate and ECG were continuously monitored in all patients. In color Doppler flow mapping, the velocity range was set at ±24.0 cm/s. First, in a 2-dimensional (D) echo, the LV was imaged in a long-axis cross-section, and the probe was then inclined laterally. Next, we examined the coronary flow in the distal portion of the LAD by color Doppler flow mapping. After a sample volume (1.5 mm wide) was positioned on the color signal in the LAD, the Doppler signals in the distal LAD were recorded (Fig 1) . Each patient was analyzed by an experienced investigator who was unaware of other details regarding the patient. Measurements were performed by tracing the contours of the spectral Doppler signal using the computer incorporated in the ultrasound system. The mean diastolic flow velocity (MDFV), peak diastolic flow velocity (PDFV) and diastolic deceleration time (DT) of the DFV were measured for augmented and non-augmented beats. The MDFV was determined from the digitized area of the diastolic flow integral. An average of 3 cardiac cycles was obtained in each setting.
Two-Dimensional Echocardiographic Measurements of LV Function
LV volume measurements were performed according to the recommendations of the American Society of Echocardiography. 18 Apical 2-and 4-chamber views were obtained at baseline. The end-diastolic and end-systolic LV volumes were computed using a modified Simpson's method. When only 1 apical view was of adequate quality for assessment, the modified Simpson's method was used in either the 4-or 2-chamber view to calculate the LV volumes. The LV ejection fraction (LVEF) was calculated as follows: (end-diastolic LV volume) -(end-systolic LV volume)/(end-diastolic LV volume) × 100.
Statistical Analysis
Data are presented as the mean ± standard deviation (SD). Group comparisons were carried out by t-test. Categorical variables were analyzed by the chi-squared test. A p-value of <0.05 was considered to be statistically significant.
Interobserver and intraobserver variabilities in the coronary flow velocity measurements were assessed in 8 randomly selected patients. Interobserver variability was calculated as the standard deviation of the differences between the measurements of 2 independent observers who were unaware of the patient's other data and expressed as a percentage of the average value. Intraobserver variability was calculated as the standard deviation of the differences between 2 measurements and expressed as a percentage of the average value.
Results

Study Patients
Adequate spectral Doppler recordings of the coronary flow in the LAD were obtained in all 17 patients using TTDE. According to the final angiographic result of the LAD, we classified the patients into the good reflow group (n=9) or the no-reflow group (n=8). In the good reflow group, 7 had anterior AMI and 2 had left main AMI. PCI to the proximal LAD was performed in these 17 patients. The characteristics and baseline data of the patients are shown in Table 1 . In the no-reflow group, myocardial blush score was 0 or 1 in all patients, whereas in the good reflow group, myocardial blush scores of 0 or 1 were found in only 11% and 89% of the group had a myocardial blush score of 3.
Effects of IABP on Systemic Hemodynamics
IABP counterpulsation reduced the systolic aortic pressure from 107±11 mmHg to 98±8 mmHg (8±6%, p<0.001) in the good reflow group and from 94±17 mmHg to 86± 8 mmHg (7±14%, p=0.01) in the no-reflow group. The diastolic aortic pressure was augmented from 67±4 mmHg to 115±16 mmHg (73±21%, p<0.001) in the good reflow group and from 58±7 mmHg to 105±12 mmHg (82±26%, p<0.001) in the no-reflow group. The baseline heart rate was 84±13 beats/min in the good reflow group and 96± 15 beats/min in the no-reflow group, and these rates remained unaffected by IABP counterpulsation.
Coronary Flow Velocity With IABP Augmentation
The spectral Doppler of the LAD flow showed a characteristic biphasic flow pattern with a larger diastolic component and a smaller systolic component. The systolic component was only clearly identified in one-third of the study patients. Therefore, we measured the mean diastolic velocities as the MDFV in this study. The coronary flow velocity data are shown in Tables 2 and 3. In the good reflow group, a rapid DT of ≤600 ms was only found in 2 patients (22%) and no early systolic retrograde flow was observed. In the no-reflow group, all 8 patients had a rapid DT of ≤600 ms, and 5 patients (63%) had early systolic retrograde flow. In the good reflow group, IABP counterpulsation increased the MDFV and PDFV by 56±32% and 48±27%, respectively, compared with the values for non-augmented beats (Figs 2A,3 ), and these changes were statistically significant (p<0.001 and p<0.001, respectively). In contrast, in the noreflow group, IABP counterpulsation increased the MDFV and PDFV by just 19±33% and 6±12%, respectively, com- 2B,3) . IABP had no effect on the DT or systolic retrograde flow between augmented and non-augmented beats ( Table 3 ). To evaluate the effects of diastolic aortic pressure on MDFV, we compared the 2 values, but there was no correlation between them (Fig 4) . Increases in MDFV by IABP also did not correlate with changes in diastolic aortic pressure by IABP ( Fig 5) . Table 4 shows the prognosis of the subjects. In-hospital prognosis was poor in patients with no-reflow. Although the LVEF was lower in the no-reflow group, it was not sig-nificantly different.
Clinical Outcomes
Observer Variabilities
The interobserver and intraobserver variabilities for the measurements of the Doppler velocity recordings were 3.0% and 2.5%, respectively.
Discussion
The results of this study demonstrate that the diastolic coronary flow velocity in the distal LAD measured by TTDE significantly increased with augmented diastolic pressure during IABP in the angiographic good reflow 
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A group. In contrast, in the angiographic no-reflow group, no significant augmentation was observed with IABP counterpulsation. These results indicate that IABP had a limited effect on the coronary flow velocity pattern in patients with the no-reflow phenomenon. To the best of our knowledge, this is the first report to evaluate the effects of IABP on coronary flow in patients with the angiographic no-reflow phenomenon in a clinical setting.
Previous Studies
The overall effects of IABP on coronary blood flow depend on both its direct effects and the indirect effects through decreasing the myocardial oxygen consumption. Whether or not the coronary flow increases during IABP counterpulsation may be explained by the relative weights of these 2 factors. Controversy surrounds the ability of IABP to increase coronary flow in critically ill patients. Human and experimental animal studies have provided conflicting data about the effects of IABP on coronary blood flow, [2] [3] [4] [5] [6] 19 and discrepancies associated with the early results may be partly related to the indirect methodologies used to measure coronary blood flow. 19 However, recent studies that have measured coronary flow velocity directly using a Doppler catheter, 2 Doppler guide wire, 3 transesophageal echocardiography 20 or transthoracic echocardiography 6 also reported different effects of IABP on coronary flow, namely that it increased 2,6 or remained unchanged. 3, 7 Some investigators 3, 5 have suggested that the inconsistency in the coronary flow velocity response during IABP may be related to differences in the severity of the coronary artery stenoses. Kern et al 4 found that IABP augmentation increased the proximal coronary flow velocity, as measured by a Doppler catheter, 4 and they also reported that coronary flow velocity was unaffected by IABP augmentation in the presence of severe coronary artery stenosis. 3 Kimura et al also showed that IABP failed to increase the diastolic coronary flow in the presence of severe coronary artery stenosis in an experimental animal study. 5 However, Takeuchi et al used TTDE and reported an increase in coronary flow with IABP augmentation, even in patients with severe coronary artery stenosis. 6 No previous study has revealed the effects of IABP on coronary blood flow in patients with the angiographic no-reflow phenomenon.
Effects of IABP on the Angiographic No-Reflow Phenomenon
Recent studies [9] [10] [11] have suggested that TIMI 1 flow after coronary reperfusion is caused by microvascular dysfunction of the ischemic region, which is recognized as the noreflow phenomenon. The occurrence of the no-reflow phenomenon during PCI has been associated with poor inhospital outcomes. [8] [9] [10] Once the no-reflow phenomenon is established, drugs such as verapamil, adenosine and sodium nitroprusside are used to treat it, 11, [21] [22] [23] and although its efficacy has not been proven in controlled trials, it is common clinical practice to use IABP in patients with the no-reflow phenomenon with the expectation of an increase in diastolic coronary flow and improved cardiac function. However, there are few reports regarding the effects of IABP on the no-reflow phenomenon in the clinical setting. Using magnetic resonance imaging in an experimental animal study, Amado et al demonstrated that IABP counterpulsation augmentation improved myocardial perfusion at the tissue level, and reduced the extent of the no-reflow caused by microvascular obstruction. 24 However, as their experimental study was not in humans, it is difficult to directly compare it with the current one. The discrepancies between our results and those in Amado et al could be related in part to the degree of microvascular damage. Recent studies using myocardial contrast echocardiography have estimated that 25-30% of AMI patients treated with PCI develop micro-vascular no-reflow, even when reperfusion is successful. 25 Although we did not perform myocardial contrast echocardiography, we used the myocardial blush score to detect a baseline microvascular level of myocardial perfusion, 15 and this showed that the angiographic no-reflow group patients all had myocardial blush scores of 0 or 1, wheras 80% of the angiographic good reflow group patients had a myocardial blush score of 3. These results indicated that the angiographic no-reflow group patients were also "no-reflow" at the microvascular level, and that most angiographic good reflow group patients were "good reflow" by the same standard. Furthermore, recent studies have demonstrated that epicardial coronary flow velocity patterns after reperfusion reflect the microvascular level of myocardial perfusion. 16, 17 Iwakura et al used a Doppler guidewire to compare coronary flow velocity patterns with myocardial contrast echocardiography in patients with anterior AMI and they concluded that the no-reflow phenomenon was characterized by the appearance of systolic retrograde flow, and rapid DT of diastolic flow. 16 Kawamoto et al also confirmed the reliability of coronary flow velocity patterns to detect microvascular damage of the infarct area; systolic retrograde flow and a rapid DT of ≤600 ms were associated with no-reflow, while a DT of >600 ms was associated with good reflow. 17 Hozumi et al showed good correlations between Dopplerguidewire-derived coronary flow reserve and TTDEderived coronary flow velocity reserve. 12 Therefore, coronary flow velocity patterns using TTDE are an appropriate and non-invasive modality for detecting the no-reflow phenomenon at the microvascular level. Our baseline DT was smaller and the prevalence of systolic retrograde flow was greater in the no-reflow group than in the good flow group, and IABP affected neither parameter. These results suggest that IABP does not influence microvascular circulation.
We evaluated the effects of IABP only as coronary flow velocity pattern during 2:1 balloon pumping. Though continuous balloon pumping may affect favorable effects on the whole heart, these effects were not evaluated in this study.
Study Limitations
Several potential limitations need to be addressed. First, we measured the coronary flow velocity, and not the coronary blood flow. However, it has been reported that changes in the coronary flow velocities closely reflect changes in the coronary blood flow when the coronary diameter remains unchanged. 26 Measurement of the coronary flow velocity was performed under well-dilated conditions using vasodilators. A previous study using a Doppler guide wire showed no significant change in the coronary diameter during IABP counterpulsation. 3 Second, we only measured mean diastolic velocities, and not mean velocities throughout 1 cardiac cycle. It was difficult to obtain the systolic flow velocity clearly because of its lower flow velocity compared with diastole. This is a limitation of measuring coronary flow velocity by TTDE. However, the diastolic coronary flow velocity is the major component of the cardiac cycle, and the diastolic component is the major component augmented by IABP counterpulsation. Third, we only applied the present method to the LAD in patients with IABP counterpulsation, because measurement of the coronary flow velocity in other coronary vessels by TTDE has not been established. Therefore, our results are limited to the LAD territory. However, the LAD is the major coronary artery and its vasculature represents the largest part of the myocardium. Finally, there was only a small number of patients with the no-reflow phenomenon and future investigations will need to include more patients.
Conclusions
IABP did not significantly augment coronary flow velocity in patients with the no-reflow phenomenon (TIMI 1 and TIMI 2 with severe delay). By contrast, IABP augmented the coronary flow velocity of the LAD in good reflow (TIMI 3) patients. These findings suggest that IABP has limited effects on LAD flow velocity pattern in patients with the no-reflow phenomenon.
